Payment overview · 2025
General Payments
$8,986.15
59 reported records · 24 companies
Healthcare provider profile · identity verified
Paul David Rosenblit, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism · HUNTINGTON BEACH, CA · NPI 1699862102
Verified facts
What the public records show
CMS Open Payments records show Paul David Rosenblit, M.D. received $8,986.15 in general payments during 2025 across 59 reported records.
Ionis Pharmaceuticals, Inc. accounted for 77.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 30 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Kerendia, Mounjaro, Ozempic, Prolia, Rybelsus, Synthroid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 196 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 252 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 193 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 661 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 661 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 171 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 371 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 436 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 126 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Ionis Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $6,926.10 | 77.1% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $285.85 | 3.2% | 9 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $278.12 | 3.1% | 8 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $258.80 | 2.9% | 9 | 2025 |
| Ascendis Pharma Endocrinology Inc | Unresolved — no canonical attribution shown | $200.91 | 2.2% | 5 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $159.24 | 1.8% | 3 | 2025 |
| RECORDATI_RARE_DISEASES_INC. | Unresolved — no canonical attribution shown | $131.95 | 1.5% | 1 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $121.83 | 1.4% | 1 | 2025 |
| Regeneron Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $75.30 | 0.8% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $66.09 | 0.7% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $61.09 | 0.7% | 2 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $56.50 | 0.6% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $46.61 | 0.5% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $45.60 | 0.5% | 2 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $44.07 | 0.5% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $33.44 | 0.4% | 1 | 2025 |
| Rhythm Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $32.86 | 0.4% | 1 | 2025 |
| Chiesi USA, Inc. | Unresolved — no canonical attribution shown | $32.02 | 0.4% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $29.39 | 0.3% | 1 | 2025 |
| Sequel Med Tech, LLC | Unresolved — no canonical attribution shown | $23.92 | 0.3% | 1 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $22.88 | 0.2% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $18.88 | 0.2% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $18.16 | 0.2% | 1 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $16.54 | 0.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $6,751.00 | 1 |
| Food and Beverage | $2,129.65 | 56 |
| Travel and Lodging | $63.00 | 1 |
| Education | $42.50 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OLEZARSEN Normalized: olezarsen |
Drug | Ionis Pharmaceuticals, Inc. | $6,926.10 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $258.80 | 9 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $233.52 | 8 | 2025 |
Source payment records
|
|||||
| Yorvipath Normalized: yorvipath |
Drug | Ascendis Pharma Endocrinology Inc | $172.83 | 4 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $159.24 | 3 | 2025 |
Source payment records
|
|||||
| ISTURISA Normalized: isturisa |
Drug | RECORDATI_RARE_DISEASES_INC. | $131.95 | 1 | 2025 |
Source payment records
|
|||||
| TEPEZZA Normalized: tepezza |
Biological | Amgen Inc. | $100.08 | 4 | 2025 |
Source payment records
|
|||||
| EVKEEZA Normalized: evkeeza |
Biological | Regeneron Pharmaceuticals, Inc. | $75.30 | 1 | 2025 |
Source payment records
|
|||||
| CRENESSITY Normalized: crenessity |
Drug | Neurocrine BioSciences, Inc. | $61.09 | 2 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $56.50 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $52.33 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $45.60 | 2 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $44.07 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $33.44 | 1 | 2025 |
Source payment records
|
|||||
| IMCIVREE Normalized: imcivree |
Drug | Rhythm Pharmaceuticals, Inc. | $32.86 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $32.64 | 2 | 2025 |
Source payment records
|
|||||
| JUXTAPID Normalized: juxtapid |
Drug | Chiesi USA, Inc. | $32.02 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $29.39 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $29.39 | 1 | 2025 |
Source payment records
|
|||||
| Skytrofa Normalized: skytrofa |
Drug | Ascendis Pharma Endocrinology Inc | $28.08 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $27.81 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $25.23 | 2 | 2025 |
Source payment records
|
|||||
| TWIIST Normalized: twiist |
Device | Sequel Med Tech, LLC | $23.92 | 1 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $22.88 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $22.42 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $18.88 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $18.16 | 1 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $16.54 | 1 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $16.54 | 1 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $16.54 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Kerendia kerendia |
2025 | Kerendia | 2024 | 193 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 171 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 436 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 54 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 126 | exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 196 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
196 | 55 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
54 | 31 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
252 | 65 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
193 | 48 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
661 | 186 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
661 | 186 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
171 | 41 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
371 | 89 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
436 | 96 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
126 | 32 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Ezetimibe | Ezetimibe | 1309 | 391 |
| Pioglitazone Hcl | Pioglitazone Hcl | 1182 | 349 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1070 | 294 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 928 | 291 |
| Atorvastatin Calcium | Atorvastatin Calcium | 902 | 267 |
| Metformin Hcl | Metformin Hcl | 765 | 243 |
| Jardiance | Empagliflozin | 661 | 186 |
| Ozempic | Semaglutide | 436 | 96 |
| Trulicity | Dulaglutide | 371 | 89 |
| Metoprolol Succinate | Metoprolol Succinate | 309 | 91 |
| Losartan Potassium | Losartan Potassium | 282 | 86 |
| Amlodipine Besylate | Amlodipine Besylate | 278 | 92 |
| Farxiga | Dapagliflozin Propanediol | 252 | 65 |
| Lisinopril | Lisinopril | 240 | 70 |
| Metformin Hcl Er | Metformin Hcl | 222 | 74 |
| Synthroid | Levothyroxine Sodium | 196 | 55 |
| Kerendia | Finerenone | 193 | 48 |
| Allopurinol | Allopurinol | 184 | 57 |
| Mounjaro | Tirzepatide | 171 | 41 |
| Hydrochlorothiazide | Hydrochlorothiazide | 129 | 39 |
| Rybelsus | Semaglutide | 126 | 32 |
| Repatha Sureclick | Evolocumab | 109 | 20 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 92 | 39 |
| Ibandronate Sodium | Ibandronate Sodium | 85 | 29 |
| Humalog Kwikpen U-100 | Insulin Lispro | 80 | 27 |
| Alendronate Sodium | Alendronate Sodium | 76 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 76 | 33 |
| Vascepa | Icosapent Ethyl | 75 | 23 |
| Glipizide Er | Glipizide | 74 | 19 |
| Glimepiride | Glimepiride | 73 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 63 | 19 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 56 | 22 |
| Prolia | Denosumab | 54 | 31 |
| Valsartan | Valsartan | 54 | 16 |
| Carvedilol | Carvedilol | 53 | 18 |
| Icosapent Ethyl | Icosapent Ethyl | 53 | 25 |
| Invokana | Canagliflozin | 53 | 13 |
| Januvia | Sitagliptin Phosphate | 51 | 17 |
| Testosterone | Testosterone | 51 | 22 |
| Simvastatin | Simvastatin | 49 | 13 |
| Calcitriol | Calcitriol | 48 | 14 |
| Tresiba Flextouch U-100 | Insulin Degludec | 47 | 17 |
| Omeprazole | Omeprazole | 45 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 44 | 15 |
| Benazepril Hcl | Benazepril Hcl | 43 | 12 |
| Pantoprazole Sodium | Pantoprazole Sodium | 43 | 13 |
| Prednisone | Prednisone | 43 | suppressed |
| Praluent Pen | Alirocumab | 41 | suppressed |
| Glipizide | Glipizide | 39 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 35 | suppressed |
| Methimazole | Methimazole | 35 | 14 |
| Fenofibrate | Fenofibrate Nanocrystallized | 34 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 34 | 11 |
| Humalog | Insulin Lispro | 33 | 12 |
| Nexlizet | Bempedoic Acid/Ezetimibe | 33 | 12 |
| Spironolactone | Spironolactone | 32 | 11 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Atenolol | Atenolol | 30 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 30 | suppressed |
| Furosemide | Furosemide | 29 | 11 |
| Gabapentin | Gabapentin | 29 | 11 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 28 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 28 | 12 |
| Bydureon Bcise | Exenatide Microspheres | 27 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | 11 |
| Fenofibrate | Fenofibrate | 26 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 26 | suppressed |
| Nexletol | Bempedoic Acid | 26 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 25 | suppressed |
| Novolog | Insulin Aspart | 24 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 24 | suppressed |
| Tradjenta | Linagliptin | 24 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 21 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 20 | suppressed |
| Hydrocortisone | Hydrocortisone | 20 | suppressed |
| Ramipril | Ramipril | 20 | suppressed |
| Irbesartan | Irbesartan | 19 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 19 | suppressed |
| Finasteride | Finasteride | 18 | suppressed |
| Lyumjev Kwikpen U-100 | Insulin Lispro-Aabc | 18 | suppressed |
| Novolog Flexpen | Insulin Aspart | 18 | 11 |
| Acarbose | Acarbose | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 16 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 16 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 16 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | Insulin Pump Cart,auto,bt,g6/7 | 15 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Pioglitazone-Metformin | Pioglitazone Hcl/Metformin Hcl | 14 | suppressed |
| Cabergoline | Cabergoline | 13 | suppressed |
| Alprazolam | Alprazolam | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 11 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $8,986.15 · 59 records | Ionis Pharmaceuticals, Inc. | AFREZZA, CRENESSITY, Dexcom G6 Transmitter, EVENITY, EVKEEZA, FREESTYLE LIBRE 3, Flector, IMCIVREE, ISTURISA, JUXTAPID, Kerendia, Korlym, LEQVIO, Licart, MOUNJARO, OLEZARSEN, Omnipod, Ozempic, PROLIA, REPATHA, REZDIFFRA, Rybelsus, SYNTHROID, Skytrofa, TEPEZZA, TWIIST, Tirosint, Wegovy, Yorvipath, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Kerendia play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error